Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06
  • 2025-05
  • 2025-04
  • Otilonium Bromide: Identity, Mechanism and Evidence

    2026-10-17

    Otilonium Bromide is described by APExBIO as a quaternary ammonium antimuscarinic agent intended for research involving cholinergic signaling and smooth-muscle pharmacology. The available product description identifies the compound as diethyl-methyl-[2-[4-[(2-octoxybenzoyl)amino]benzoyl]oxyethyl]azanium bromide and reports a molecular weight of 563.57. It also lists a stated purity of at least 98%, aqueous, dimethyl sulfoxide, and ethanol solubility specifications, and availability as either a solid or a 10 mM solution in DMSO. These details are product-level information, not results from an identity-matched pharmacology study. The source is the Otilonium Bromide catalog entry.

    Documented identity and scientific context

    The catalog places the compound within the antimuscarinic class and links it to neuroscience and smooth-muscle research. That framing gives the material a plausible conceptual role in studies where muscarinic acetylcholine-receptor signaling is part of the biological question. It does not, by itself, establish a particular receptor subtype, tissue selectivity, potency ranking, or suitability for a specific cellular, neural, gastrointestinal, or contractility model.

    The term “acetylcholine receptor inhibitor” should also be interpreted cautiously. Acetylcholine receptors include muscarinic and nicotinic receptor families, whereas “antimuscarinic” specifically signals a muscarinic-receptor context. The product description uses both broad acetylcholine-receptor language and the narrower antimuscarinic classification, but it does not provide subtype-resolved binding or functional data that would justify treating Otilonium Bromide as a uniformly active inhibitor across all AChR classes.

    Documented mechanism and measurement meaning

    According to the product description, Otilonium Bromide acts by inhibiting acetylcholine receptors and thereby modulating cholinergic signaling pathways. Read mechanistically, this is an upstream perturbation: the proposed molecular action is receptor-level interference with acetylcholine-mediated signaling. A change in a downstream readout—such as a signaling marker, neuronal response, or smooth-muscle behavior—would therefore be compatible with altered cholinergic input, but would not on its own prove direct receptor binding, identify the receptor subtype involved, or exclude other explanations.

    This distinction matters in both neuroscience receptor modulation and smooth muscle spasm research. A functional readout may integrate receptor occupancy, receptor distribution, signal amplification, tissue state, and pathway compensation. Consequently, the product description supports a mechanistic hypothesis about muscarinic signaling, not a quantitative claim about the size, direction, or reproducibility of any downstream response.

    Claim or property What the product description reports Appropriate interpretation
    Compound identity Quaternary ammonium antimuscarinic agent; molecular weight 563.57 Supports catalog-level chemical classification and identity, but not independent structural confirmation.
    Mechanism Inhibition of acetylcholine receptors with modulation of cholinergic signaling Defines a proposed receptor-mediated mechanism; no subtype, affinity, kinetic, or functional antagonist values are supplied.
    Research context Neuroscience and smooth-muscle pharmacology Indicates intended conceptual application areas, not demonstrated performance in a named model.
    Purity and solubility At least 98% purity and stated solvent-specific solubility values Describes catalog specifications and physicochemical handling characteristics; it does not establish cellular activity, selectivity, or assay reproducibility.
    Available forms Solid powder or a 10 mM DMSO solution Describes supplied formats; the concentration is not evidence of a biologically effective concentration or a validated experimental condition.

    Interpreting the supplied properties and scope

    The reported purity and solubility values may be relevant to how a material is characterized as a research product, but they should not be conflated with pharmacological evidence. Purity does not establish the absence of biologically relevant impurities under every analytical context, and solubility does not establish membrane access, receptor engagement, intracellular exposure, or stability in a biological matrix. Similarly, a supplied DMSO formulation identifies a product format rather than demonstrating compatibility with a particular biological assay.

    The stated research scope is correspondingly broad. Cholinergic signaling is involved in multiple physiological systems, but the product record does not document results in a specific neuronal preparation, smooth-muscle preparation, or gastrointestinal motility disorder model. It therefore cannot support claims about disease-model efficacy, translational benefit, or clinical treatment. Nor does it establish that an observed change in gastrointestinal motility, contractility, viability, or neuronal activity would be uniquely attributable to muscarinic antagonism.

    Evidence availability and applicability boundaries

    No identity-matched research paper is available for this editorial. As a result, there are no documented sample sizes, comparators, effect sizes, confidence intervals, dose–response relationships, receptor-binding measurements, or downstream outcome statistics to report. The absence of those data is not evidence that such studies do not exist elsewhere; it means only that they are not present in the materials available here.

    The related promotional articles listed with the product do not supply a verifiable, identity-matched study design or quantitative result in the available summaries. They are therefore not treated as independent evidence for Otilonium Bromide’s mechanism or performance. In particular, broad claims about reproducibility, “precise” receptor inhibition, assay robustness, or translational application cannot be accepted from product-oriented language alone.

    Several boundaries follow directly from this evidence situation:

    • The catalog description supports a muscarinic-cholinergic research context, but not a receptor-subtype map or potency profile.
    • A downstream signal or physiological response would require separate evidence to distinguish receptor inhibition from pathway adaptation, tissue-specific effects, assay interference, or other pharmacological explanations.
    • Catalog purity, solubility, storage, and formulation statements do not substitute for stability, exposure, selectivity, or functional studies in the relevant biological system.
    • Applications in neuroscience, smooth-muscle spasm research, or gastrointestinal motility disorder models remain conceptual categories unless supported by model-specific publications.

    Factual synthesis

    APExBIO presents Otilonium Bromide as a quaternary ammonium antimuscarinic research compound with a proposed role in inhibiting acetylcholine-receptor signaling. The most defensible interpretation is that it represents a catalog-defined pharmacological perturbant for questions involving muscarinic cholinergic pathways. The available information does not establish subtype selectivity, quantitative receptor pharmacology, downstream effect sizes, or performance in any named model. Researchers should therefore distinguish the product’s documented identity and stated mechanism from evidence that would be needed to interpret biological outcomes in a particular experimental system.